Download Oncology Nursing Drug Handbook - v3.5.13

Download Oncology Nursing Drug Handbook - v3.5.13
Package Name com.medpresso.Lonestar.oncondh
Category ,
Latest Version 3.5.13
Get it On Google Play
Update June 26, 2020 (4 years ago)

You've heard of Oncology Nursing Drug Handbook - v3.5.13, or MCQ Abubakr (ASU), Dexcom G6, Medical Dictionary Free & Offline - Diseases, Jan Aushadhi Sugam (BPPI), Medical PG, FMGE Preparation - PrepLadder, NYP, one of the coolest APPS of the genre Medical.

And of course you know that, not all games or applications are compatible for all phones. The game or application is sometimes not available on your device, it depends on the version of the system. Android operating system, screen resolution, or countries that Google Play allows access to.That is why APKPanda provides Android APK files for you to download and doesn't stick to these restrictions. >
Oncology Nursing Drug Handbook - v3.5.13 latest version is 3.5.13, release date 2020-06-25, and has size 8.4 MB.Developed by Skyscape Medpresso Inc, Oncology Nursing Drug Handbook - v3.5.13 requires Android version at least Android 5.0+. Therefore you must update your phone if necessary.

Pretty much loaded, about 1000 downloads. You can update apps that have been downloaded or installed individually on your Android device if you want. Updating your apps gives you permission access to the latest features and improve application security and stability.

Oncology Nursing Drug Handbook - v3.5.13

Written especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

DESCRIPTION
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.

Key Features

- Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
- Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
- Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
- Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
- New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)

Faster download with slow internet connectivity

Show more